Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3998985 | Surgical Oncology Clinics of North America | 2008 | 18 Pages |
Abstract
Tremendous progress has been made in surgery for cancer of the esophagus and gastroesophageal junction. After primary surgery, overall 5-year survival rates of 35% or more are obtained in high-volume units, and for advanced stage III cancer, 5-year survival reaches 25%. Multimodality therapy, in particular induction chemotherapy with or without radiotherapy, results in a complete response rate in up to 25% of the patients. Approximately 50% of the patients receiving such treatment do not respond, however, and their outcome is dismal. Therefore, further efforts are needed to elaborate more precise algorithms for selecting candidates for induction therapy versus primary surgery.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Toni Lerut, Johnny Moons, Willy Coosemans, Herbert Decaluwé, Georges Decker, Paul De Leyn, Philippe Nafteux, Dirk Van Raemdonck,